Arvinas, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
ARVN Nasdaq 2834 www.arvinas.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Arvinas, Inc.

How The Arvinas (ARVN) Story Is Evolving As 2026 Neurology Catalysts Approach - Apr 4th, 2026 8:11 pm
Arvinas (ARVN) Moves 6.9% Higher: Will This Strength Last? - Apr 2nd, 2026 12:55 am
Arvinas Announces Positive Phase 1 Data for ARV-102 Showing Greater Than 50% LRRK2 Degradation in the CSF of Patients with Parkinson’s Disease Treated for 28 Days - Mar 18th, 2026 5:00 am
Arvinas to Present Phase 1 Data for ARV-102, a PROTAC LRRK2 Degrader, in Oral Session at the 2026 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders - Mar 11th, 2026 5:00 am
Arvinas Highlights Phase 1 Shift, 2026 Data Catalysts, and Vepdegestrant NDA at Barclays Conference - Mar 11th, 2026 2:21 am
Arvinas Teases Near-Term Phase 1 Data, Eyes New Vepdegestrant Partner at Leerink Conference - Mar 10th, 2026 1:03 am
How The Arvinas (ARVN) Narrative Is Evolving With New Leadership And Key 2026 Pipeline Catalysts - Mar 6th, 2026 3:09 am
Arvinas Highlights Growing Phase 1 Pipeline, Near-Term Catalysts at TD Cowen Healthcare Conference - Mar 4th, 2026 8:36 am
Arvinas, Inc. (ARVN) Makes Significant Progress on Oncology and Neurology Trials - Mar 2nd, 2026 12:57 am
Arvinas Inc (ARVN) Q4 2025 Earnings Call Highlights: Navigating Revenue Challenges with ... - Feb 24th, 2026 12:01 pm
Arvinas (ARVN) Q4 2025 Earnings Call Transcript - Feb 24th, 2026 12:00 pm
Arvinas, Inc. Q4 2025 Earnings Call Summary - Feb 24th, 2026 10:32 am
Arvinas Q4 Earnings Call Highlights - Feb 24th, 2026 8:44 am
Arvinas, Inc. (ARVN) Reports Q4 Loss, Misses Revenue Estimates - Feb 24th, 2026 7:40 am
Arvinas Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - Feb 24th, 2026 5:00 am
Arvinas to Participate in Upcoming Investor Conferences - Feb 23rd, 2026 5:00 am
Arvinas to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026 - Feb 17th, 2026 5:00 am
Arvinas Announces Appointment of Randy Teel, Ph.D., as President, Chief Executive Officer, and Director - Feb 12th, 2026 5:00 am
Here's Why We're Not Too Worried About Arvinas' (NASDAQ:ARVN) Cash Burn Situation - Jan 12th, 2026 3:48 am
Arvinas Presents Preclinical Data Supporting Mechanistic Synergies and Enhanced Antitumor Activity with the Combination of ARV-393 and Glofitamab at the 2025 American Society of Hematology Annual Meeting and Exposition - Dec 6th, 2025 6:05 am